Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity

Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor...

Full description

Saved in:
Bibliographic Details
Published inJournal of Neural Transmission Vol. 121; no. 4; pp. 379 - 383
Main Authors Bartl, Jasmin, Müller, Thomas, Grünblatt, Edna, Gerlach, Manfred, Riederer, Peter
Format Journal Article
LanguageEnglish
Published Vienna Springer Vienna 01.04.2014
Springer Nature B.V
Subjects
Aged
Aged, 80 and over
Dose-Response Relationship, Drug
Female
Humans
Indans - therapeutic use
Male
Medicine
Medicine & Public Health
Middle Aged
Monoamine Oxidase - blood
Monoamine Oxidase Inhibitors - therapeutic use
Neurology
Neurology and Preclinical Neurological Studies - Short communication
Neurosciences
Parkinson Disease - blood
Parkinson Disease - drug therapy
Psychiatry
Selegiline
MAO-B inhibitors
MAO-A
Rasagiline
Parkinson’s disease
Online AccessGet full text

Cover

More Information
Summary:Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily.
ISSN:0300-9564
1435-1463
DOI:10.1007/s00702-013-1120-z